🔗 Permalink

Inventor profile of:

Leon Murphy

City:

Cambridge, Massachusetts

Country:

United States

Published Applications:

28

Last publication date:

2023-07-13

Top Assignees for applications by Leon Murphy

The entities that hold a legal rights for patent applications filed by inventor Murphy Leon:

NOVARTIS AG 17 Basel, Switzerland
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 14 PHILADELPHIA, PA United States
Jennifer Brogdon 3 Cambridge, MA United States
David Glass 3 Cambridge, MA United States
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2 Cambridge, MA United States
Joan Mannick 2 Cambridge, MA United States
Abhishnek Garg 1 Cambridge, MA United States
Jan J. Melenhorst 1 Cherry Hill, NJ United States
Michael J. Milone 1 Cherry Hill, NJ United States
Leon J. Murphy 1 Cambridge, MA United States
Elena J. Orlando 1 Somerville, MA United States
Nicholas J. Wilcox 1 Southlake, TX United States
Qilong H. Wu 1 Basel, PA Switzerland
Qilong H. Wu 1 Philadelphia, PA United States
Gregory Beatty 1 Philadelphia, PA United States
Carl H. June 1 Merion Station, PA United States
Joan H. Mannick 1 Cambridge, MA United States
Michael H. Milone 1 Cherry Hill, NJ United States
Leon H. Murphy 1 Cambridge, MA United States
Gabriela H. Plesa 1 Blue Bell, PA United States
Huijuan H. Song 1 Shanghai, PA China
Qilong H. Wu 1 Shanghai, PA China
Michael C. Milone 1 Cherry Hill, NJ United States
Leon C. Murphy 1 Cambridge, MA United States
Felipe Bedoya 1 Medford, MA United States
Hans Bitter 1 Lincoln, MA United States
Corin Dorfmeier 1 Hayfield, PA United States

Recent patent applications by Murphy Leon

Leon Murphy from Cambridge, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2023-07-13

US20230220090A1

Chemistry; metallurgy

TREATMENT OF CANCER USING A CD123 CHIMERIC ANTIGEN RECEPTOR

#2 | 2023-02-16

US20230052970A1

Chemistry; metallurgy

PHOSPHOGLYCERATE KINASE 1 (PGK) PROMOTERS AND METHODS OF USE FOR EXPRESSING CHIMERIC ANTIGEN RECEPTOR

#3 | 2023-01-26

US20230026049A1

Chemistry; metallurgy

REGULATABLE CHIMERIC ANTIGEN RECEPTOR

#4 | 2022-03-03

US20220064316A1

Chemistry; metallurgy

Treatment of cancer using humanized anti-BCMA chimeric antigen receptor

#5 | 2021-06-10

US20210172020A1

Chemistry; metallurgy

BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO CHIMERIC ANTIGEN RECEPTOR THERAPY AND USES THEREOF

#6 | 2021-02-04

US20210030741A1

Human necessities

PHARMACEUTICAL COMBINATION OF EVEROLIMUS WITH DACTOLISIB

#7 | 2021-01-07

US20210002377A1

Chemistry; metallurgy

Treatment of cancer using a CD123 chimeric antigen receptor

#8 | 2020-10-29

US20200339651A1

Chemistry; metallurgy

METHODS FOR B CELL PRECONDITIONING IN CAR THERAPY

#9 | 2020-07-09

US20200215171A1

Human necessities

TREATMENT OF CANCER USING A CLL-1 CHIMERIC ANTIGEN RECEPTOR

#10 | 2020-02-20

US20200054742A1

Human necessities

LOW, IMMUNE ENHANCING, DOSE MTOR INHIBITORS AND USES THEREOF

#11 | 2019-12-26

US20190388471A1

Human necessities

TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR

#12 | 2019-08-29

US20190263914A1

Chemistry; metallurgy

Regulatable chimeric antigen receptor

#13 | 2019-05-23

US20190153061A1

Chemistry; metallurgy

Anti-BCMA chimeric antigen receptor

#14 | 2018-12-27

US20180369370A1

Human necessities

Low, immune enhancing, dose MTOR inhibitors and uses thereof

#15 | 2018-11-22

US20180334490A1

Chemistry; metallurgy

METHODS FOR B CELL PRECONDITIONING IN CAR THERAPY

#16 | 2018-11-01

US20180312595A1

Chemistry; metallurgy

Treatment of cancer using a CD123 chimeric antigen receptor

#17 | 2018-10-11

US20180289694A1

Human necessities

Pharmaceutical combination of everolimus with dactolisib

#18 | 2018-05-03

US20180118834A1

Chemistry; metallurgy

Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor

#19 | 2017-10-26

US20170306416A1

Chemistry; metallurgy

Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof

#20 | 2017-10-05

US20170281753A1

Human necessities

Low, immune enhancing, dose mtor inhibitors and uses thereof

#21 | 2017-09-28

US20170274014A1

Human necessities

COMBINATIONS OF LOW, IMMUNE ENHANCING, DOSES OF MTOR INHIBITORS AND CARS

#22 | 2016-10-27

US20160311907A1

Chemistry; metallurgy

Regulatable chimeric antigen receptor

#23 | 2016-04-07

US20160096892A1

Chemistry; metallurgy

Treatment of cancer using a CD33 chimeric antigen receptor

#24 | 2016-03-10

US20160068601A1

Chemistry; metallurgy

Treatment of cancer using a CD123 chimeric antigen receptor

#25 | 2016-02-25

US20160051651A1

Human necessities

Treatment of cancer using a CLL-1 chimeric antigen receptor

#26 | 2016-02-18

US20160046724A1

Chemistry; metallurgy

Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor

#27 | 2015-10-08

US20150283178A1

Human necessities

Treatment of cancer using anti-CD19 Chimeric Antigen Receptor

#28 | 2015-05-21

US20150140036A1

Human necessities

LOW, IMMUNE ENHANCING, DOSE MTOR INHIBITORS AND USES THEREOF

InventorID:

1167644 ⎘